Pancreatic Cancer Research

ResearcherUniversity of SienaNo recent work listed

Roberto Petrioli

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5047413929. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 4 papers · 2021: none · 2022: 3 papers · 2023: 2 papers

Papers 10

  1. Clinical outcome and safety profile of metastatic pancreatic cancer patients treated with more than six cycles of nab-paclitaxel plus gemcitabine. Co-author DOI 10.1080/1120009x.2023.2190712↗
  2. Prognostic value of alkaline phosphatase and gamma-glutamyl transferase in patients with metastatic pancreatic cancer. Co-author DOI 10.2217/fon-2023-0137↗
  3. The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients with metastatic pancreatic cancer. Co-author DOI 10.1038/s41598-022-12214-4↗
  4. Risk Factors for Nab-Paclitaxel and Gemcitabine-Induced Peripheral Neuropathy in Patients with Pancreatic Cancer. Co-author DOI 10.1159/000524868↗
  5. Capecitabine as a Second-line Treatment for Older Patients with Pancreatic Cancer. Last author DOI 10.2174/1389201023666220307090450↗
  6. Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or meta… Co-author DOI 10.1016/j.jgo.2019.08.008↗
  7. Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer. Co-author DOI 10.1038/s41598-020-76465-9↗
  8. FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer. Co-author DOI 10.2147/cmar.s267393↗
  9. Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: The NAPA Study. Co-author DOI 10.2174/1568009620999200918122426↗
  10. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study. Co-author DOI 10.1007/s00280-015-2683-1↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Giandomenico Roviello · 9 shared papers, 2015–2023 · strength 1.35
  2. Monica Ramello · 8 shared papers, 2020–2023 · strength 1.29
  3. Martina Catalano · 8 shared papers, 2020–2023 · strength 1.29
  4. Giuseppe Aprile · 4 shared papers, 2022–2023 · strength 0.74
  5. Alberto D’Angelo · 3 shared papers, 2020–2023 · strength 0.40
  6. Enrico Mini · 3 shared papers, 2020–2023 · strength 0.39
  7. Edoardo Francini · 2 shared papers, 2015–2020 · strength 0.17
  8. Daniele Marrelli · 1 shared paper, 2015 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.